In pre-clinical models, PARP inhibition upregulates the expression of programmed death ligand 1 (PD-L1) on the surface of cancer cells and synergistically enhances the activity of immune checkpoint inhibitors targeting PD-(L)1 [40,41], providing a biologic rationale for PARP/PD-(L)1 dual inhibition. Here, CD274 is linked to cancer.